Literature DB >> 15197775

Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract.

Mario Sarbia1, Helene Geddert, Bodo Klump, Sybille Kiel, Erol Iskender, Helmut Erich Gabbert.   

Abstract

Aberrant promoter methylation is an important mechanism for gene silencing. In the present study, 50 Barrett's esophagus-associated esophageal adenocarcinomas (ADC), 50 cardiac ADC and 50 gastric ADC were investigated by means of methylation-specific real-time PCR for hypermethylation in the tumor suppressor genes APC, p16(INk4A) and p14(ARF). Additionally, expression of p16(INK4A) protein in the carcinomas was assessed using immunohistochemistry. Marked differences in hypermethylation were found between esophageal, cardiac and gastric ADC in the APC gene (78% vs. 32% vs. 84%) and in the p16(INK4A) gene (54% vs. 36% vs. 10%). Hypermethylation of p14(ARF) was absent from esophageal ADC and present infrequently in cardiac (2%) and gastric ADC (10%). Complete loss of p16(INK4A) protein expression was detectable in 45% of all tumors and was significantly associated with hypermethylation of the p16(INK4A) gene (p<0.0001, chi(2)-test). Our results suggest that hypermethylation of p16(INK4A) and APC are frequent findings in esophageal, cardiac and gastric ADC. Additionally, the data point to a tumor specific methylation pattern in upper gastrointestinal ADC. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15197775     DOI: 10.1002/ijc.20212

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

Review 1.  Epigenetic biomarkers in esophageal cancer.

Authors:  Andrew M Kaz; William M Grady
Journal:  Cancer Lett       Date:  2012-03-07       Impact factor: 8.679

2.  The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens.

Authors:  Mario Sarbia
Journal:  Virchows Arch       Date:  2006-02-24       Impact factor: 4.064

3.  Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1.

Authors:  Nicholas J Clemons; Hongdo Do; Christina Fennell; Siddhartha Deb; Andrew Fellowes; Alexander Dobrovic; Wayne A Phillips
Journal:  Dig Dis Sci       Date:  2014-01       Impact factor: 3.199

Review 4.  Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.

Authors:  Andrew M Kaz; William M Grady; Matthew D Stachler; Adam J Bass
Journal:  Gastroenterol Clin North Am       Date:  2015-04-01       Impact factor: 3.806

5.  EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1.

Authors:  Helene Geddert; Axel zur Hausen; Helmut E Gabbert; Mario Sarbia
Journal:  Cell Oncol (Dordr)       Date:  2011-05-03       Impact factor: 6.730

Review 6.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

7.  Methylation of a single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancer.

Authors:  Xiang Zhang; Mengchu Wu; Hong Xiao; Ming-Tsung Lee; Linda Levin; Yuet-Kin Leung; Shuk-Mei Ho
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

8.  Relationship between the extent of chromosomal losses and the pattern of CpG methylation in gastric carcinomas.

Authors:  Seung-Jin Hong; Young-Ho Kim; Young-Deok Choi; Ki-Ouk Min; Sang-Wook Choi; Mun-Gan Rhyu
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

9.  Cause and consequences of genetic and epigenetic alterations in human cancer.

Authors:  B Sadikovic; K Al-Romaih; J A Squire; M Zielenska
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

10.  Gastroesophageal reflux leads to esophageal cancer in a surgical model with mice.

Authors:  Jing Hao; Ba Liu; Chung S Yang; Xiaoxin Chen
Journal:  BMC Gastroenterol       Date:  2009-07-23       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.